Effects of localised tumour hyperthermia on pimonidazole (Ro 03-8799) pharmacokinetics in mice. by Walton, M. I. et al.
B) The Macmillan Press Ltd., 1989
Effects of localised tumour hyperthermia on pimonidazole (Ro 03-8799)
pharmacokinetics in mice
M.I. Walton, N.M. Bleehen & P. Workman
MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge CB2 2QH, UK.
Summary We have investigated the effects of localised tumour hyperthermia (LTH; 43.5°C x 30min) on the
acute toxicity and pharmacokinetics of the hypoxic cell sensitizer pimonidazole (Ro 03-8799) in mice. There
were three treatment groups: unrestrained controls, sham-treated and LTH treated mice. LTH had minimal
effects on the acute toxicity (LD5o/7d) of pimonidazole with no significant difference between the three
treatment groups. Pharmacokinetic studies were carried out at the maximum tolerated dose (MTD; -60%
LD50) of 437pgg-1 i.v. in plasma, brain and tumour. Sham tumour treatment consistently increased plasma
drug concentrations compared to unrestrained controls but had minimal effects on the elimination t1/2. The
AUC0_ was increased by 35% and the plasma clearance decreased by 26%. By contrast, LTH had minimal
effects on these parameters compared to sham treatment. Brain pimonidazole concentrations were increased in
restrained mice (sham and LTH treatments) compared to unrestrained controls, but average brain/plasma
ratios were similar in all three groups at between 400 and 500%. Sham tumour treatment markedly reduced
peak tumour pimonidazole concentrations compared to unrestrained controls giving a 29% lower
AUCo-180min. Average tumour/plasma ratios were reduced from 236 to 129%. The most important finding
was that LTH further reduced pimonidazole tumour concentrations, giving a 31% lower AUCo-180min
compared to sham treated tumours. Tumour/plasma ratios for pimonidazole were reduced by 41%. Plasma
exposure to the pimonidazole N-oxide metabolite, Ro 31-0313, was unaltered by LTH. The markedly reduced
drug concentrations in heated tumours may be a result of hyperthermia-stimulated bioreductive drug
activation.
Hyperthermia (42-450C) enhances the cytotoxic effects of
radiation towards tumour cells both in vitro (Sapareto et al.,
1978) and in vivo (Mittal et al., 1984). In addition local
hyperthermia shows promise for clinical use (for reviews see
Arcangeli et al., 1988; Perez & Meyer, 1985).
Localised tumour hyperthermia (LTH) also potentiates the
tumour cytotoxicity of certain drugs (Englehardt, 1987),
including the electron-affinic 2-nitroimidazole radiosensitizer
misonidazole (Bleehen et al., 1977), in experimental tumours.
The addition of misonidazole to LTH and X-rays can
increase the local tumour control rates for this latter
combination in mice (Overgaard, 1980; Wondergem et al.,
1982). Furthermore, a preliminary clinical study with the
three modalities combined showed increased complete
response rates in superficial neck node tumours compared to
either radiotherapy alone or any pair of modalities together
(Arcangeli et al., 1980). Misonidazole is, however, unlikely to
achieve optimal radiosensitization in man as a result of its
dose-limiting neurotoxicity (e.g. Wasserman et al., 1979;
Dische et al., 1982), and less neurotoxic and/or more potent
analogues are undergoing development (Bartelink et al.,
1988).
Pimonidazole (o-[(2-nitro-1-imidazolyl)methyl]-1-piperi-
dine-ethanol; Ro 03-8799), is a basic, lipophilic derivative
exhibiting more efficient radiosensitization than
misonidazole in vitro (Smithen et al., 1980). It was hoped that
its pKa (8.7) would facilitate excretion in acidic urine and
thereby reduce total-body exposure and hence toxicity
(Wardman, 1979). The basicity of this molecule also appears
to result in accumulation within cultured cells and their
lysosomes and also binding to purified DNA (Stratford et
al., 1988; Dennis et al., 1985). The drug also concentrates in
tumours in vivo, resulting in tumour/plasma ratios in excess
of 200% in mice and humans (Stratford et al., 1982; Allen et
al., 1984; Roberts et al., 1986). Similar ratios have been
reported in several normal tissues as well (Williams et al.,
1982; Roberts et al., 1986).
Tumour tissues commonly exhibit pHs values below 7.4
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(Wike-Hooley et al., 1984). Factors contributing to acidosis
include poor tumour blood perfusion resulting in reduced
oxygen tension (p02), increased anaerobic glycolysis and
decreased clearance of acidic metabolites (for a review see
Calderwood & Dickson, 1983). LTH can reduce blood-flow
in rodent tumours (Dudar & Jain, 1984; Song, 1984;
Reinhold et al., 1985) and has been shown to reduce both
intracellular (Evanochko et al., 1983) and extracellular
(Wike-Hooley et al., 1984) tumour pH, possibly through
heat-stimulated anaerobic glycolysis and/or as a result of
hyperthermia-induced disruptions in tumour blood-flow
(Calderwood & Dickson, 1983; Reinhold et al., 1985). A
hyperthermia-induced drop in pH might be expected to
increase tumour uptake of basic drugs such as pimonidazole
from plasma (Wardman, 1982; Calderwood & Dickson,
1983), providing drug availability is not blood-flow limited.
The selection of pimonidazole for use with hyperthermia
may therefore be particularly appropriate. In addition,
hyperthermia has also been shown to enhance the reductive
bioactivation of nitro compounds in vitro (Walton et al.,
1987b; Olive, 1978).
In view of the enhanced cytotoxicity of nitroimidazole
radiosensitisers with hyperthermia and the current clinical
interest in radiotherapy combined with either radiosensitisers
(e.g. Brown, 1986) or LTH (e.g. Overgaard, 1984), the
possibility of combining all three modalities for the
treatment of human cancer is an attractive one (Herman et
al., 1988). Because of the particular pharmacokinetic
advantages which exist for pimonidazole compared to
misonidazole and because of its continuing clinical
development, we have investigated the effects of LTH on the
acute toxicity, pharmacokinetics and metabolism of
pimonidazole. In particular we have attempted to answer the
following questions. (1) Does LTH alter the acute toxicity of
pimonidazole? (2) Does LTH alter pimonidazole
pharmacokinetics and selectively enhance tumour drug
uptake? (3) Do the hyperthermia-drug interactions have a
pharmacokinetic explanation and/or offer new information
on the effects of LTH on drug metabolism? Such
information should provide a useful guide to the potential
efficacy of combining pimonidazole, LTH and radiotherapy
in the clinic.
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Materials and methods
Mice and tumours
Adult male C3H/He mice were obtained from our own
breeding colony or from Olac Ltd (Bicester, UK). Mice were
allowed food (PRD nuts; Labsure, Poole, Dorset) and water
ad libitum, and were used at 25-33 g body weight.
The KHT sarcoma was grown in the gastrocnemius
muscle of the right hind leg as previously described
(Twentyman et al., 1979). Mice were treated bearing tumours
of 11-13mm (orthodiagonal diameters) for pharmacokinetic
experiments.
Drug supply and administration
Pimonidazole, its N-oxide Ro 31-0313 (ac[(2-nitro-l-
imidazolyl)methyl]-1-piperidine-ethanol 1-oxide) and the
internal standard Ro 07-1902 (1-(2-nitroimidazol-1-
yl)allyloxy propanol) were supplied by Roche (Welwyn
Garden City, UK). Pimonidazole was supplied as the
hydrochloride salt and all doses and concentrations are
reported as the free base.
Drugs were administered in Hanks' balanced salt solution
(HBSS, pH 7.4) at a fixed volume of 0.01 mlg-1 body weight
via the tail vein. Pimonidazole was injected over 35-40s to
avoid death by vascular shock (Williams et al., 1982). Drugs
were administered 5min before LTH.
Localised tumour hyperthermia (LTH)
This was administered to unanaesthetised mice using a
computer-controlled radiofrequency (RF)-waterbath heating
system which produces uniform tumour heating with
minimal increases in core (rectal) temperature (Walton et al.,
1989b). Approximately 2min after drug administration mice
were loaded into special perspex LTH jigs so that their
shaved tumour-bearing legs were located between the RF
electrodes. The LTH exposure was 43.5°C x 30min, which is
equal to a dose in equivalent minutes at 43°C (Eq 43) of
42.2min (Dunlop et al., 1984). This hyperthermia dose and
treatment did not result in tumour oedema or normal tissue
toxicity (see Walton et al., 1989b). Groups of 3-4 mice were
treated at the same time. Mice were allocated to three
different protocols: (1) combined RF-waterbath LTH at
43.5°C x 30min; (2) sham tumour treatment in perspex jigs
without LTH but with the tumour bearing leg placed in a
waterbath at 37°C; and (3) no treatment (unrestrained
controls). After LTH and sham treatment, mice were rubbed
dry with tissue paper and briefly warmed under a 40W lamp
to prevent post-treatment hypothermia.
Acute toxicity
The effect of LTH on the acute toxicity (LDIo/7d) of
pimonidazole was determined using tumour-bearing animals
as described elsewhere (Walton et al., 1987a). Mice were
allocated to one of the three different protocols described
above. Graded doses of 524-900pgg-1 pimonidazole were
given to groups of 4-5 mice with 3-4 doses per treatment.
Mice were observed for 7 days post-treatment. LD50/7d
values and confidence limits were derived using pooled data
from three experiments by probit analysis, using the
Generalised Interactive Modelling Program (GLIM) of the
Royal Statistical Society of London.
Sample analysis
Samples were prepared and analysed as described in detail
elsewhere (Walton et al., 1987a). Briefly, whole blood was
removed from anaesthetised animals and plasma obtained by
centrifugation. Drugs were extracted into 10 volumes of
acetonitrile containing the internal standard (Ro 07-1902)
and taken to dryness before resuspension in 100 p1 of
running buffer prior to HPLC analysis. After exsanguination
animals were killed by cervical dislocation, and tumour and
brain tissue was rapidly removed and snap-frozen on dry ice
to prevent ex vivo metabolism. Tissue samples were
homogenised (33% w/v) in distilled water before drug
extraction and analysis as for plasma samples. All samples
were handled on ice and stored at -20°C for up to 4 weeks
before analysis.
Drug concentrations were assayed by reverse-phase,
paired-ion, isocratic HPLC using a modified version of the
method of Malcolm et al. (1983) as described elsewhere
(Walton et al., 1987a). Chromatography was carried out
using columns and equipment supplied by Waters Ass.
(Milford, MA, USA). Separations were performed on
reverse-phase octadecylsilane (C18) Rad-Pak p Bondapak
columns (10cm x 8mm i.d., 10pm bead size) eluted
isocratically with 17% acetonitrile in 0.2M glycine/
hydrochloric acid buffer containing 5mM heptane sulphonic
acid, pH2.45, at a flow rate of 4.5mlmin-1. Absorbance
was monitored at 313 nm. Pimonidazole and Ro 31-0313
were identified by co-chromatography with authentic
material and quantitated by peak-height ratio with reference
to linear standard curves.
Pharmacokinetic parameters
Standard pharmacokinetic parameters (see Wagner, 1975)
were calculated as described in detail elsewhere (White &
Workman, 1980; Workman & Brown, 1981) using a one- or
two-compartment model with curve stripping as appropriate.
Lines of best fit were calculated by least squares linear
regression analysis yielding half-lives with 95% confidence
limits. Plasma area under the concentration x time curve
(AUCO o) was calculated from the expression
AUCO =Co/k, where CO is the concentration at time 0 and
k is the elimination rate constant, or from the equation
AUCO =A/o +B/#, as appropriate. Tissue AUC0_, from
time 0 to time t was estimated by Simpson's rule.
Statistics
Significance levels were determined using the Student's t test.
Results
Effects of LTH on pimonidazole acute toxicity
Table I summarises the effects of LTH on the acute lethality
(LD50/7d) of pimonidazole in mice. LTH had no significant
effect on pimonidazole toxicity compared to sham tumour
treatment (P>0.5), and drug plus sham tumour treatment
was no more toxic than in unrestrained controls (P>0.05).
Deaths were either rapid and convulsive, occurring during or
immediately after drug injection and before jig loading, or
non-convulsive and occurring during the subsequent 24h.
No deaths resulted during the period of either LTH or sham
tumour treatments.
Table I Effects of LTH on the acute
Toxicity LD50/7d(ggl)
C3H mice.
Toxicity LD5o/7d(Y9gg1)
Unrestrained Sham LTH
control treatment treatment
758 775 710
(720-798) (726-829) (551-829)
Results were obtained using pooled
data from three independent experiments
with 4-5 mice per dose and 3-4 doses
per experiment. 95% confidence limits
are shown in parentheses.LOCAL HYPERTHERMIA AND Ro 03-8799 PHARMACOKINETICS 669
Subsequent pharmacokinetic studies were carried out at
the previously determined maximum tolerated dose (-60%
LD50/7d) in unrestrained control mice of 437pgg- (see
Walton et al., 1987a) as this was similar to the MTD for
unrestrained mice determined here (P>0.2). Mice were given
either pimonidazole alone or pimonidazole combined with
LTH or sham tumour treatment. No deaths occurred at this
dose in any treatment group (total number of mice=46).
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Effects of LTH and pimonidazole on tumour and core
temperatures
High doses of 2-nitroimidazoles cause hypothermia in mice
(Gomer & Johnson, 1979), and the dose of pimonidazole
used in these LTH experiments has previously been shown to
decrease mouse rectal temperature by 2-3°C for up to 1 h
after administration (Walton et al., 1987a). In view of this,
we determined the effects of LTH applied 5min after
437 pgg- 1 pimonidazole i.v. on tumour and rectal
temperatures.
Figure 1 shows that central tumour temperatures reached
43.5°C about 4min after the start of heating and were
maintained to within 0.2-0.3°C (range) of the target
temperature for the majority of the treatment. This
hyperthermia treatment (43.5°C x 35min) gave a total
thermal dose measured in equivalent minutes at 43°C (Eq
43) of 40.8+0.35min (mean +2s.e.; n=4), which represents
97% of the prescribed dose. Average core temperatures
increased slightly over the heating period from about 36 to
37CC, and were consistently I°C higher than in unrestrained
control mice given this dose of pimonidazole alone (Walton
et al., 1987a).
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Effects of LTH on pimonidazole pharmacokinetics
Plasma pharmacokinetics. Pimonidazole plasma clearance
was biphasic in unrestrained control mice (Figure 2a). The
initial x-phase was short (t1/2o o-2.5 min) and essentially
complete within the first 10min after drug administration,
while the terminal f-phase was much longer with a t1/2f
(with 95% confidence limits) of 31.3 (28.9-34) min. As the
error in treating these data as monoexponential was small
(5.7%) they were fitted to a one-compartment model in
accordance with the guidelines of Dvorchik & Vesell (1978).
Figure 2a shows that plasma drug concentrations were
consistently higher in mice with sham-treated tumours
compared to unrestrained control mice, with significant
increases at 90, 120 and 180min (P<0.05 in each case). The
elimination t1/2 were highly comparable (P>0.5) but sham
tumour treatment reduced the apparent Vd by 18%
compared to the value in unrestrained controls (P<0.05).
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Figure 1 The effects of LTH (43.5CC x 30min) started 5 min
after 437 pg g - pimonidazole i.v. on the central tumour (0) and
rectal (E]) temperatures in C3H mice bearing KHT leg tumours.
Results are mean+2 s.e. for a typical LTH treatment using four
mice. Similar results were obtained in repeat experiments.
Figure 2 The effects of LTH (43.5'C x 30min) on the pharma-
cokinetics of pimonidazole in (a) plasma, (b) brain and (c)
tumour tissue of C3H mice administered 437jugg-1 pimonida-
zole i.v. Symbols: A unrestrained control mice; 0 sham tumour
treated mice; * LTH treated mice. Results are mean +2 s.e.
Pooled data from two independent experiments each involving 5-
8 time points with 3-4 mice per point. Lines fitted by least-
squares linear regression analysis.
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The AUCO was increased by 35% and the plasma
clearance (Pc,) correspondingly reduced by 26% in sham
tumour treated compared to unrestrained control mice.
By comparison, LTH did not further affect plasma
pimonidazole concentrations compared to sham tumour
treatment (Figure 2a), and the respective elimination t1/2s
were also very similar (Table II; P>0.5). In addition Vd,
AUCO oo and P,, were minimally altered by LTH compared
to sham tumour treatment (Table II).
Brain pharmacokinetics. Brain pimonidazole concentrations
reached a peak of around 340 ugg-1 in both unrestrained
controls and mice with sham-treated tumours, though it was
much broader in the latter group (Figure 2b). Brain
pimonidazole concentrations were consistently higher during
the elimination phase in mice bearing sham-treated tumours
compared to unrestrained controls, in accord with their
higher plasma drug concentrations; this difference was
significant at 90, 120 and 180min (P<0.05, P<0.01 and
P<0.05 respectively). There was no difference between brain
elimination t112 for unrestrained control and sham tumour
treated mice (P>0.3), but AUC,180mim'values were
reproducibly increased by an average 13% in the latter
group (Table II).
LTH had minimal effects on brain pimonidazole
pharmacokinetics compared to sham tumour treatment.
LTH did not significantly alter either brain drug
concentrations or the elimination t1/2 (P>0.2). AUCo-180min
values were very similar.
After equilibration at 60min, brain/plasma ratios were
similar in all three treatment groups at between 360 and
628% (range). For example brain/plasma ratios at 50 or
60min were 402+113, 393+66.6 and 364+60.5%
(mean+2s.e.; n=6) in unrestrained control, sham tumour
Table II Summary of the effects of LTH on the pharmaco-
kinetics of pimonidazole (437,gg-1 i.v.) in plasma, brain
and KHT tumour of C3H mice
Treatment
Unrestrained Sham LTH
control treatment treatment
Plasma
t1/2
(min)
Vdext
(mlg-)
AUCo-o
(Mgml- h)
PC]
(mlg-lh-)
Brain
t1/2
(min)
AUCO 180min
(gg 1gh)
Tumour
tlm2
(min)
31.3
(28.9-34)
2.59a
(2.21-3.05)
127
(135, 127)
3.44
(3.23, 3.44)
31.6
(29-34.6)
441
(434, 477)
34.7
(32.3-37.5)
2.12
(1.86-2.41)
172
(168, 175)
2.54
(2.60, 2.50)
33.9
(30.7-37.8)
529
(503, 586)
36.0
(32.9-39.8)
2.30
(1.97-2.69)
165
(145, 184)
2.65
(3.01, 2.38)
38.4
(32.9-46.1)
499
(393, 617)
31.6 35.2 33.6
(29.1-33.3) (30.7-41.2) (30.1-37.9)
AUCo0180min 268 191 132
(igg'h) (263, 299) (235, 157) (152, 116)
Parameters were derived using pooled data from two
independent experiments. These were fitted to a one-
compartment model. 95% confidence limits are shown in
parentheses for tI12 and Vd values. Figures in parentheses for
AUC and Pcl represent the values determined in two indepen-
dent experiments (A and B, respectively). Each experiment
involved 7-8 time points with 3-9 mice per point. ap<0.05
significantly different from sham treatment. The unrestrained
control t112 and the LTH t1/2 and Vd values were not
significantly different from sham-treatment values (P>0.05).
and LTH treated mice respectively, values in good agreement
with previous work (Walton et al., 1987a). Average steady-
state brain/plasma ratios (mean +2 s.e.; n=22) were very
similar at 498+64, 454+34 and 433+38% for unrestrained
control mice and those bearing sham- and LTH-treated
tumours respectively (P>0.05).
Tumour pharmacokinetics. Tumour pimonidazole concen-
trations in unrestrained control mice reached a peak of
about 250Mgg-1 20-30min after administration (Figure 2c).
The elimination t1/2 was 31.6min and the AUCo-180m.i was
441 Mgg- h (Table II). Sham-treated tumours had a 2-fold
lower peak concentration, the difference being highly signifi-
cant at 20min (P<0.01). However, the levels became similar
during the terminal elimination phase (Figure 2c). Sham
tumour treatment had minimal effects on tumour t1/
(P>0.1), but reduced the AUC,180m, by 29% compared to
the value in unrestrained control tumours.
LTH had a very marked effect on tumour pimonidazole
concentrations compared to sham-treated tumours (Figure
2c). Locally heated tumours had a lower peak drug concen-
tration and exhibited consistently reduced drug levels over
the whole time course compared to sham-treated, giving
significantly different zero time intercepts for each treatment
(P<0.05). This reduction in pimonidazole concentrations in
heated tumours occurred despite the higher plasma drug
concentrations in these mice. The average AUCo-180m.i was
decreased by 31% compared to sham-treated tumours. The
tumour AUCo0180mmi was decreased by 35 and 26% in the
two independent experiments. LTH did not significantly alter
pimonidazole tumour elimination t1/2 which were similar in
all three treatment groups (P>0.1).
Table III shows the tumour/plasma ratios from the above
data. Tumour/plasma ratios in unrestrained control mice
consistently exceeded 200% after equilibration at 20min, in
good agreement with other values (Williams et al., 1982;
Walton et al., 1987a). Ratios in sham-treated tumours were
consistently less than those in unrestrained controls. Average
ratios were stable from 10-180min and exceeded 100% after
35min but were all <175%. The overall mean ratios were
significantly reduced in sham-treated tumours from 236+ 16.9
to 129+17% (mean+2s.e.; n=31 and 40 respectively;
P<0.001).
LTH had even more pronounced effects on tumour drug
concentrations compared to sham tumour treatment. LTH
markedly reduced tumour/plasma ratios over the whole time
course with significant decreases at 35, 120 and 180min
(Table III). In addition, steady-state ratios never exceeded
100% in heated tumours and the average tumour/plasma
ratio over this period was significantly reduced from 129 + 17
to 87.8+10.9% (mean +2s.e.; n=40; P<0.001).
Effects of LTH on pimonidazole N-oxidation
Figure 3 shows the plasma concentrations of Ro 31-0313,
the N-oxide metabolite of pimonidazole, after pimonidazole
administration alone, or combined with LTH or sham
tumour treatment. Peak plasma concentrations of Ro 31-
0313 were increased during LTH compared to sham-treated
mice, e.g. by 34% from 9.77 to 13.1 pgml-l at 20min
(P<0.05). However, the plasma AUCo0180mmi was essentially
unaffected. The values in the two independent experiments
were 19.3 and 23.5 compared to 18.4 and 22.5pgml-1 h for
LTH and sham-treated mice respectively. Plasma Ro 31-0313
concentrations in unrestrained control mice were consistently
lower than for sham tumour treated mice. This resulted in a
25% lower AUCo0 80mmi of 14.9Mgml1h, the values in two
independent experiments being 14.6 and 16.1 Mgml-1 h.
Tumour and brain Ro 31-0313 levels were frequently at or
just above the lower limit of detection (-. 1Mgg-1). Maxi-
mum tumour Ro 31-0313 concentrations did not exceed
7,gg-1 giving a tumour/plasma ratio of 43%, while maxi-
mum brain concentrations did not exceed 3.5,ugg-I corres-
ponding to a brain/plasma ratio of 63%.LOCAL HYPERTHERMIA AND Ro 03-8799 PHARMACOKINETICS 671
Table III Effects of LTH on the tumour/plasma ratios for
pimonidazole (437pgg-' i.v.) in C3H mice
Time after drug
administration
(min)
rto
LTH 20
35
50
60
90
120
180
Tumour/plasma (%)
Unrestrained Sham LTH
control treatment treatment
179+20.8b
(n=4)
219+ 11.3b
(n =9)
ND
266+ 35.3
(n=6)
ND
250 + 70.9a
(n=6)
238 +20.0O
(n=6)
205+ 19.5b
(n =4)
98.3 +26.3
(n=6)
96.6+ 11.4
(n=6)
155 +42.7
(n=6)
ND
118 + 58.1
(n=6)
136+ 55.4
(n=6)
175 +42.4
(n=6)
124+25.8
(n=4)
91.2 + 52.8
(n=6)
87.9 + 18.9
(n =6)
93.1 + 18.9a
(n=6)
ND
87.6+ 39.8
(n=6)
88.7 +21.0
(n=6)
82.9+ 20.2b
(n=6)
81.1 +20.la
(n=4)
Results are mean +2 s.e. of n values which were derived
using pooled data from two independent experiments. ap<
0.05 and bP<0.01 significantly different from sham treatment.
ND, Not determined.
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Figure 3 Plasma concentrations of the N-oxide metabolite Ro
31-0313, after pimonidazole administration (437 pgg- 1 i.v.) in
C3H mice. Symbols: V unrestrained control mice; O sham tumour
treated mice; and * LTH treated mice. Results are mean +2s.e.
using pooled data from two independent experiments with 4-9
mice per point.
Discussion
The toxicological results show that LTH (43.5°C x 30min)
does not increase the acute toxicity of pimonidazole in mice
whose core temperatures were maintained at 36-38°C. This
is in marked contrast to the situation with whole-body
hyperthermia (WBH; 41°C x 35min) where pimonidazole
acute toxicity was increased 3-fold (Walton et al., 1987a).
Misonidazole and etanidazole (SR 2508) lethality were also
enhanced by WBH (Bleehen et al., 1988). Other investigators
have observed increased misonidazole acute lethality in mice
treated with LTH (Overgaard, 1979; Bleehen et al., 1977) but
rectal temperatures approached 41°C towards the end of
heating. Cisplatinum acute lethality has also been shown to
increase with LTH (44°C x 60min) in rats (Mella, 1985) and
systemic cooling reduced this toxicity. If hyperthermia-
enhanced acute drug toxicity in mice results from elevated
systemic temperatures, as appears to be the case, then careful
body temperature regulation will be required in order to
minimise these effects during LTH.
The pharmacokinetic results show that sham tumour
treatment resulted in elevated plasma drug concentrations
compared to unrestrained controls without affecting the
elimination t1/2. Consequently, mice bearing sham-treated
tumours had a lower Vd, higher AUC0 -, and a correspond-
ingly slower Pc1 than unrestrained controls. Furthermore, the
results also show that LTH has no significant effect on
pimonidazole plasma concentrations or t1/2 in mice. It has
minimal effects on plasma AUC0 -o or Pcl, though Vd was
slightly increased. This difference between restrained mice
(both LTH and sham tumour treated) compared to unres-
trained control mice may result from stress-impaired renal
drug clearance under the former conditions.
Unrestrained control mice had slightly lower brain pimoni-
dazole levels than sham tumour treated animals. This was
almost certainly due to their lower plasma pimonidazole
concentrations, as equilibration with plasma was comparable
resulting in very similar brain/plasma ratios. Pimonidazole
concentrated in brain tissue to a similar degree in sham
tumour and LTH treated mice with brain/plasma ratios of
between 400 and 600% (range).
Tumour/plasma ratios in unrestrained control mice equili-
brated at between 205 and 266%, values comparable though
slightly lower than in previous reports (Williams et al., 1982;
Walton et al., 1987a). Sham-treated tumour pimonidazole
drug concentrations were slightly less than those in unre-
strained control tumours, giving nearly a 2-fold lower aver-
age tumour/plasma ratio of 129%. This reduction in
pimonidazole concentrations in sham-treated tumours could
have arisen through altered blood perfusion or metabolism
in the tumour-bearing leg as a result of stress or direct
restriction. If so, then not all handling artifacts have been
removed from this system, and LTH might be more effi-
cacious if applied after peak tumour drug levels have been
attained.
Perhaps the most consistent and important effect of LTH
was its ability substantially to reduce tumour concentrations
of pimonidazole over the whole time course, giving a 31%
lower AUCo0 80mmi in heated tumours compared to sham-
treated ones. Tumour/plasma ratios were also significantly
lower in locally heated tumours with a 41% decrease in the
average steady-state ratio. This finding is similar to that
reported for MISO and LTH (44°Cx60min; Honess et al.,
1980) where nitroimidazole concentrations in heated tumours
were reduced by up to 70% giving a 25% lower AUCO-8b
and a reduction of up to 65% in heated tumour/plasma
ratios compared to controls. Decreased tumour/plasma
ratios in heated tumours may be the result of several factors.
[Fhere is evidence that LTH can decrease or abolish tumour
blood-flow (Bicher et al., 1980; Dudar & Jain, 1984; Song,
1984). This might lead to reduced drug supply to the tumour
and consequently lower tumour drug uptake. Moreover, if
hyperthermia-decreased tumour pH occurs as a result of the
accumulation of metabolic waste products through heat-
impaired tumour blood perfusion, then LTH might not
increase tumour uptake of basic drugs from the plasma
because of limited drug supply.
An alternative explanation is that LTH stimulates the
nitroreductive bioactivation of pimonidazole to non-UV
absorbing metabolites (Schwartz & Hofheinz, 1982), a pro-
cess strongly implicated in the hypoxic cytotoxicity of 2-
nitroimidazoles (Taylor & Rauth, 1978; Rauth, 1984).
Further support for this hypothesis comes from our studies
where LTH increased KHT tumour concentrations of the
reduced amine metabolite of the 2-nitroimidazole benznida-
zole (Walton et al., 1989a) and other work where LTH
(43°C x 60min) increased concentrations of reduced adriamy-
cin metabolites, especially aglycones, in murine tumours
(Magin et al., 1980). Adriamycin aglycone production in rat672 M.I. WALTON t a/l.
liver slices is also enhanced by elevated temperatures under
anaerobic conditions in vitro (Dodion et al., 1986). As
pimonidazole is stable for at least 2h at 43.5°C in sodium
phosphate buffer (pH 7.4) and mouse plasma (Walton et al.,
unpublished data) heat-enhanced spontaneous chemical
degradation can be ruled out.
LTH increased peak plasma concentrations of the pimoni-
dazole N-oxide metabolite Ro 31-0313 during heating. This
may reflect an increase in oxidative metabolism and/or
decreased plasma clearance of the metabolite. This finding is
in marked contrast to WBH where pimonidazole N-
oxidation was greatly elevated in mouse plasma during and
after the heating period (Walton et al., 1987a). Previous
studies with MISO have shown that LTH decreases peak
plasma concentrations of the 0-demethylated metabolite of
misonidazole, though the metabolite AUCs were comparable
in heated and control mice (Honess et al., 1980).
In summary, LTH did not alter the acute lethality of
pimonidazole in mice. It had minimal effects on plasma and
brain pimonidazole pharmacokinetics, and only slightly
increased plasma N-oxide concentrations. However, tumour
drug concentrations were significantly decreased by LTH,
possibly through heat-stimulated reductive bioactivation.
These results show that LTH has a complex effect on
pimonidazole tumour pharmacokinetics and metabolism.
Further studies are required to elucidate the effects of
hyperthermia on oxidative and reductive metabolism, par-
ticularly in view of the cytotoxic potential of the latter
reaction in hypoxic cells and its possible enhancement in
locally heated tumours. Combinations of LTH with hypoxic-
cell targeted radiosensitisers and other bioreductive drugs are
likely to require further addition of radiation or appropriate
drugs to eliminate the oxic cell population.
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help with the statistical analyses and we are also grateful to Mrs J.
Shaw for care of the animals. M. Walton thanks the Cancer
Research Campaign for a research studentship award.
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